PBYI News and Press, Puma Biotechnology Inc From 02/26/21

Puma Biotechnology (PBYI) and CANbridge Pharmaceuticals have agreed to terminate their 2018 license agreement, in which Puma granted CANbridge exclusive rights to develop and commercialize NERLYNX (neratinib) in Greater China, and to settle their arbitration related to the license agreem...

Puma Biotechnology, Inc. (PBYI) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director of Investor Relations Alan Auerbach – President, Chairman and Chief Executive Officer Jeff Ludwig – Chief Commercial Offi...

Puma Biotechnology (PBYI): Q4 Non-GAAP EPS of -$0.14 misses by $0.05; GAAP EPS of -$0.38 misses by $0.06.Revenue of $52.6M (-16.4% Y/Y) misses by $0.09M.Press Release For further details see: Puma Biotechnology EPS misses by $0.05, misses on revenue

Puma Biotechnology (PBYI) and  French pharmaceutical company Pierre Fabre have agreed to extend the terms of the 2019 license agreement which grants Pierre Fabre exclusive rights to develop and commercialize NERLYNX (neratinib) within Europe, Turkey, Mi...

Puma Biotechnology and CANbridge Pharmaceuticals Terminate License Agreement in Greater China Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pierre Fabre, a leading French pharmaceutical company, have agreed to extend the terms of the 2019 lice...

Puma Biotechnology (NASDAQ:PBYI) is scheduled to announce Q4 earnings results on Thursday, February 25th, after market close.The consensus EPS Estimate is -$0.09 and the consensus Revenue Estimate is $52.69M (-16.2% Y/Y).Over the last 2 years, PBYI has beaten EPS estimates 88% of the tim...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 25, 2021, following release of its fourth quarter and full year 2020 financial results. The call may be accessed by dialing 1-877-70...

Puma Biotechnology (PBYI) perks up 6% after presenting interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer patients with epidermal growth factor exon 18 mutations.The interim efficacy results showed that for the 10 e...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor (EGFR) exon 18 mutations who have been previous...

The following slide deck was published by Puma Biotechnology, Inc. in conjunction with this event. For further details see: Puma Biotechnology (PBYI) Special Call - Slideshow